Vivodyne to Replace Animal Testing With $40 Million Funding to Reverse 95% Clinical Trial Failure Rate

Vivodyne获4000万美元融资，将取代动物测试以扭转95%的临床试验失败率

• 95% of clinical trials fail because animal testing is no substitute for human biology - Vivodyne’s robotics platform grows thousands of human tissues daily, directly tackling the biological gap behind clinical failures.

• 95%的临床试验失败是因为动物测试无法替代人类生物学——Vivodyne的机器人平台每天培养数千个人类组织，直接解决了导致临床失败的生物学差距。

• Vivodyne’s AI generates clinically predictive human datasets, already in use by most of the world’s top pharmaceutical firms.

• Vivodyne的人工智能生成临床上具有预测性的人类数据集，已被世界上大多数顶级制药公司使用。

• Series A, led by Khosla Ventures, accelerates delivery of AI-led human predictive insights with a new 23,000 sq ft San Francisco facility.

Khosla Ventures领投的A轮融资加速了AI主导的人类预测洞察的交付，并在旧金山设立了新的23,000平方英尺的设施。

SAN FRANCISCO & PHILADELPHIA, May 29, 2025-- Biopharmaceutical companies routinely cure diseases in animals during preclinical testing, yet those same therapies fail in human clinical trials nearly 95% of the time. By shifting from animals to an exclusively human optimization preclinical process, Vivodyne has raised $40 million in new Series A financing to scale its robotics+AI approach to testing on thousands of lab-grown, fully-functional human tissues, and the massive amount of human data they generate.

旧金山和费城，2025年5月29日——生物制药公司通常在临床前试验中治愈动物的疾病，但同样的疗法在人体临床试验中几乎95%的时间都失败了。通过从动物试验转向完全基于人类优化的临床前流程，Vivodyne已筹集了4000万美元的新一轮A轮融资，以扩大其机器人+人工智能技术在数千个实验室培育的、功能齐全的人体组织上的测试规模，以及它们所产生的海量人体数据。

With the new financing, Vivodyne will open a 23,000-square-foot fully robotic laboratory at Genesis Marina in South San Francisco. The new facility significantly increases preclinical human testing capacity to meet surging demand from global pharmaceutical clients, particularly spurred on by the recent commitments by FDA and NIH to move away from less-predictive animal models..

通过这笔新的融资，Vivodyne 将在南旧金山的 Genesis Marina 开设一个 23,000 平方英尺的全机器人实验室。该新设施将大幅提高临床前人体测试能力，以满足全球制药客户激增的需求，特别是受到 FDA 和 NIH 最近承诺放弃较低预测性的动物模型的推动。

The investment was led by Khosla Ventures, with participation from new investors Lingotto Investment Management, Helena Capital, Fortius Ventures, and existing investors Kairos Ventures, CS Ventures, Bison Ventures, and MBX Capital.

本轮融资由Khosla Ventures领投，新投资者Lingotto Investment Management、Helena Capital、Fortius Ventures以及现有投资者Kairos Ventures、CS Ventures、Bison Ventures和MBX Capital共同参与。

Vivodyne’s advance is designed to get better drug candidates into human testing. Until now, preclinical R&D relied on experimental iteration that optimized candidate drugs so that they worked successfully in animals, without any human-specific refinement. Vivodyne allows the same refinement process but directly on human tissues, generating people-ready drug candidates for the first time..

Vivodyne的进步旨在将更好的药物候选者推进到人体试验阶段。迄今为止，临床前研发依赖于实验迭代来优化候选药物，使其在动物体内成功起效，但没有任何针对人类的改进。Vivodyne实现了同样的优化过程，但直接在人体组织上进行，首次生成了适用于人类的药物候选者。

“Vivodyne is fundamentally changing how drugs move from the lab bench to human trials,” said Andrei Georgescu, Ph.D., CEO and co-founder of Vivodyne. “A model that is only predictive 5% of the time isn’t a model. We’re redefining success in drug discovery by overcoming the limitations that have stalled scientific progress for decades.”.

“Vivodyne 正在从根本上改变药物从实验室走向人体试验的方式，” Vivodyne 首席执行官兼联合创始人 Andrei Georgescu 博士说道。“一个仅有 5% 预测准确率的模型不能称之为模型。我们正在通过克服几十年来阻碍科学进步的局限性，重新定义药物发现的成功标准。”

While animal models share proteins and pathways with humans, their similarities to human disease are often surface-deep, undermining their predictive power. Vivodyne enables large-scale clinical testing on lab-grown human tissues that can recapitulate the complexity of human disease, leading to more accurate results.

虽然动物模型与人类共享蛋白质和通路，但它们与人类疾病的相似性往往仅限于表面，削弱了其预测能力。Vivodyne 能够在实验室培养的人体组织上进行大规模临床测试，这些组织可以重现人类疾病的复杂性，从而获得更准确的结果。

This enables pharmaceutical companies to leverage these fully functional tissues across the entire preclinical pipeline, from initial target discovery through clinical candidate selection through safety and efficacy testing, significantly improving success rates in human trials. This has the potential to accelerate drug discovery by replacing largely unreliable, slow-growing animal models with vast, unified datasets of human tissue responses..

这使得制药公司能够在整个临床前管道中利用这些功能齐全的组织，从最初的目标发现到临床候选药物的选择，再到安全性和有效性测试，从而显著提高人体试验的成功率。通过用大量统一的人体组织反应数据集取代很大程度上不可靠、生长缓慢的动物模型，这有可能加速药物的发现。

“Pharma has waited decades for scalable human data before clinical trials,” continued Georgescu. “We’re now generating data from tens of thousands of complex human tissues, capturing immune responses and disease states that were previously inaccessible. This unprecedented scale and resolution unlock entirely new avenues for drug development.”.

“制药行业在临床试验前已经等待了数十年可扩展的人类数据，”乔治斯库继续说道。“我们现在正在从数万个复杂的人体组织中生成数据，捕捉以前无法获得的免疫反应和疾病状态。这种前所未有的规模和分辨率解锁了药物开发的全新途径。”

Vivodyne removes the scientific uncertainty of relying on animal models for testing by producing human multi-omic data, including imaging, single-cell transcriptomics, and proteomics from more than 10,000 independent human-tissue experiments per robotic run. Vivodyne’s tissues are a thousand times larger than typical organoids, enabling detailed, functional analyses of human drug responses.

Vivodyne通过生成人类多组学数据（包括成像、单细胞转录组学和蛋白质组学）消除了依赖动物模型进行测试的科学不确定性，这些数据来自每次机器人运行的超过10,000个独立的人体组织实验。Vivodyne的组织比典型的类器官大一千倍，能够对人类药物反应进行详细的功能分析。

Its fully automated robotic workflow ensures reproducibility at AI-scale throughput, generating more reliable, human-relevant data annually than all U.S. clinical trials combined..

其全自动机器人工作流程确保了在人工智能规模的吞吐量下结果的可重复性，每年生成的数据比所有美国临床试验加起来还要多，且更可靠、更贴近人类相关性。

'Robotics and AI are already starting to fundamentally change the healthcare landscape and Vivodyne is pioneering the way there,' said Vinod Khosla, founder of Khosla Ventures. 'Using robotics and AI, Vivodyne can grow and test over 100,000 different whole human tissues automatically within two weeks, enabling pharma to achieve human-equivalent insights before committing billions of dollars to clinical trials.”.

“机器人技术和人工智能已经开始从根本上改变医疗保健领域的格局，而 Vivodyne 正在引领这一潮流，”Khosla Ventures 创始人 Vinod Khosla 表示。“通过使用机器人技术和人工智能，Vivodyne 可以在两周内自动培养和测试超过 10 万种不同的人体组织，使制药公司能够在投入数十亿美元进行临床试验之前获得与人类等效的洞察。”

Most of the world’s leading pharmaceutical companies rely on Vivodyne’s technology because drug failures often stem from flawed assumptions about biological targets, pathway mechanisms, and how those pathways affect human tissues.

世界上大多数领先的制药公司都依赖 Vivodyne 的技术，因为药物研发失败往往源于对生物靶点、通路机制以及这些通路如何影响人体组织的错误假设。

Vivodyne’s AI-driven platform actively designs and optimizes a wide range of therapies, including small molecules, biologics (antibodies and antibody-drug conjugates), mRNA-based lipid nanoparticles, and cell therapies.

Vivodyne的人工智能驱动平台积极设计和优化多种疗法，包括小分子、生物制品（抗体和抗体药物偶联物）、基于mRNA的脂质纳米颗粒以及细胞疗法。

Ileana Pirozzi, Lingotto Investment Management, added, “Vivodyne’s systems grow over 20 distinct human tissue types, including bone marrow, lymph nodes, liver, lung, placenta, and models diseases such as cancer, fibrosis, autoimmunity, and infections. With AI assistance, these systems iteratively learn and improve, actively adapting to optimize therapeutic discovery and patient stratification outcomes.”.

伊莱娜·皮罗齐，Lingotto投资管理公司补充道：“Vivodyne的系统培育超过20种不同的人体组织类型，包括骨髓、淋巴结、肝脏、肺、胎盘，并模拟癌症、纤维化、自身免疫和感染等疾病。在人工智能的协助下，这些系统不断学习和改进，积极适应以优化治疗发现和患者分层结果。”

About Vivodyne

关于Vivodyne

Vivodyne is rendering inaccurate animal testing obsolete, using automated robotic platforms and AI to grow and analyze thousands of fully functional human tissues. Pharmaceutical companies historically have spent millions on clinical trials destined to fail 95% of the time because animal models are poor predictors of human biology.

Vivodyne正在通过使用自动化机器人平台和人工智能来培养和分析数千个完全功能性的人体组织，从而使不准确的动物实验变得过时。制药公司历史上在临床试验上花费了数百万美元，但这些试验有95%的失败率，因为动物模型对人类生物学的预测能力较差。

Vivodyne solves this problem by providing unprecedented, clinically relevant human data at massive scale. Already used by most top pharma companies, Vivodyne’s platform significantly reduces trial risk, accelerates drug discovery, and brings safer, more effective therapies to patients faster. For more information, visit www.vivodyne.com.

Vivodyne通过提供前所未有的、大规模的临床相关人类数据来解决这一问题。目前已被大多数顶级制药公司使用，Vivodyne的平台显著降低了试验风险，加速了药物发现，并更快地为患者带来更安全、更有效的治疗方法。欲了解更多信息，请访问www.vivodyne.com。

Contact:

联系人：

Media Contact

媒体联系人

Consort Partners for Vivodyne

维沃戴恩的联合伙伴

vivodyne@consortpartners.com

维沃戴恩@康索特合伙公司. com